Giannakaki-Zimmermann H, Behrndt A, Hoffmann L, et al. - Researchers conducted the study for analyzing longer-term functional and morphological outcomes and their predictors in diabetic macular edema (DME) following a treat and extend regimen (TER) without loading dose under ranibizumab. Patient data were reviewed and retrospectively analyzed over the 24-month period following TER initiation. Best-corrected visual acuity, treatment frequency as well as quantitative and qualitative Spectral-domain Optical Coherence Tomography parameters have been evaluated. Participants in the study were 87 patients (118 eyes). The use of ranibizumab in TER without a loading dose in DME substantially improves visual acuity and retinal anatomy over a two-year period. The predictors evaluated could help to direct the routine clinical treatment of DME.